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Effects of ranolazine in patients with acute coronary syndrome and stable
angina according to whether they undergo percutaneous coronary
intervention: Observations from the MERLIN-TIMI 36 Trial
Benjamin Scirica1, Sabina Murphy1, Ewa Karwatowska-Prokopczuk2,
Gennyne Walker2, Luiz Belardinelli2, Ori Ben-Yehuda2, David Morrow1
1TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham
and Women’s Hospita, Boston, MA, 2Gilead Sciences, Forest City, CA
Background: Ranolazine is a late sodium current (late INa) inhibitor with anti-ischemic
effects that is indicated for the treatment of stable angina. Patients with a history stable
angina who subsequently are admitted with ACS are at particularly high risk of recurrent
ischemic events. We examined the 1-year incidence of recurrent CV events in patients
with prior angina who had PCI within 30 days of the index event and whether ranolazine
offered any incremental benefit compared to placebo.
Methods: 3565 patients in the MERLIN-TIMI 36 trial, which randomized patients with
NSTE-ACS to ranolazine vs. placebo, reported a history of prior stable angina. The
primary endpoint was the composite of CV death, MI, or recurrent ischemia (RI) defined
as ischemia w/ ECG changes, leading to hospitalization, prompting revascularization, or
worsening of stable angina prompting intensification of therapy.
Results: In this cohort of patients with prior angina presenting with NSTEACS, 914
patients underwent PCI within 30 days of randomization. Overall, patients who underwent
PCI had lower rates of CV death, but higher rates of RI and MI than patients who did not
undergo PCI. Ranolazine reduced the risk of RI regardless of whether patients did or did
not have PCI (21.3 v. 29.8%, HR 0.71, p0.011 and 14.7 v. 18.2%, HR 0.81, p0.03).
Ranolazine significantly reduced the risk of the primary endpoint, CV death, and RI
leading to revascularization in patients who underwent PCI, whereas there was no benefit
among patients who did not undergo PCI.
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135 29.3% 164 38.8% 0.73 0.007 308 23.7% 339 26.3% 0.91 0.24 0.12
CV death 7 1.7% 17 3.8% 0.39 0.027 97 7.0% 84 6.3% 1.19 0.25 0.016
MI 46 9.9% 48 10.7% 0.89 0.58 100 7.7% 104 8.2% 0.98 0.9 0.71
Recurrent
ischemia
98 21.3% 122 29.8% 0.71 0.011 179 14.7 222 18.2% 0.81 0.03 0.43
Recurrent
ischemia
leading to
revasc
45 9.4% 72 16.8% 0.55 0.01 32 2.7% 39 2.9% 0.82 0.39 0.18
Conclusions: Regardless of whether patients underwent PCI or not for the treatment of
ACS, ranolazine reduced the risk of recurrent ischemia during the 1 year following
admission. In patients who did have PCI within 30 days of admission, rates of the primary
endpoint and recurrent ischemia were lower in patients treated with ranolazine.
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Triple Versus Dual Antiplatelet Therapy in Patients with Acute Myocardial
Infarction and Renal Insufficiency:Results from Korea Acute Myocardial
Infarction Registry
Sang Yup Lim1
1Korea University Ansan Hospital, Ansan, Korea, Republic of
Background: Whether triple antiplatelet therapy is superior or not to dual antiplatelet
therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous
coronary intervention in the era of renal insufficiency remains unclear.
Methods: As a part of the Korea Acute Myocardial Infarction Registry (KAMIR), 2288
AMI patients with renal insufficiency (GFR 60 ml/min) received either dual (aspirin
plus clopidogrel; n1587) or triple (aspirin plus clopidogrel plus cilostazol; n701)
antiplatelet therapy. Major adverse cardiac event (MACE) at 1- month and 1-year were
compared between these two groups.
Results: Compared with the dual group, the triple group had a similar incidence of major
bleeding events but a significantly lower incidence of in-hospital mortality. MACE rate at
1 month was significantly higher in the dual group than that of triple (16.3 % vs. 11.1%,
p0.05), which was mainly due to death rather than re-PCI (12.9 % vs. 9.1%, p0.05).
However, MACE rate at 1-year and MACE free survival day was not different between
two groups.
Conclusions: In AMI patients with renal insufficiency, triple antiplatelet therapy exhibits
a favorable in-hospital and short-term MACE event, but no difference in 1-year MACE
free survival.
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P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in
Patients with Chest Pain with Prior History of Coronary Artery Stenting in
Emergency Department
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Background: Dual anti-platelet regimen has been shown to reduce major adverse
cardiovascular events (MACE) after percutaneous coronary interventions (PCI). Variable
response to clopidogrel can lead to pharmacodynamic failure, which may translate into
clinical failure. We conducted a study to evaluate factors associated with hyporespon-
siveness to clopidogrel with P2Y12 reactivity units by VerifyNow in previously stented
patients presenting to the emergency department (ED) with chest pain while they were on
dual anti-platelet regimen.
Methods: Hyporesponsiveness to clopidogrel was evaluated in a cohort of 531 consec-
utive patients with history of coronary artery stenting, presenting to ED with chest pain.
Patients were labeled hyporesponders if they had P2Y12 Reactivity Units (PRU)  230.
221 patients (41.6%) had PRU230. A multivariable logistic regression model was used
to determine the relationship between clopidogrel hyporesponsiveness and several
potential risk factors, including gender, age, race, type I diabetes, type II diabetes,
hypertension, smoking, chronic renal failure, and obesity.
Results: Out of this cohort of 531 patients, three predictors were statistically significant
at p0.05 (see table below): Type II diabetes (adjusted odds ratio, AOR2.109), black
race (AOR2.165), and female gender (AOR1.813). Age was a moderately significant
predictor (p0.058, AOR1.167 per decade).
Variable Estimate Std Error z value Pr(>|z|) AOR 95% CI
Gender
(female)
0.595 0.191 3.113 0.0019 1.813 1.248 2.641
Age (decades) 0.155 0.082 1.899 0.0575 1.167 0.996 1.372
Race (Black) 0.772 0.215 3.589 0.0003 2.165 1.423 3.312
Type I diabetes -0.109 0.692 -0.158 0.8747 0.897 0.212 3.432
Type II diabetes 0.746 0.206 3.618 0.0003 2.109 1.410 3.166
Hypertension -0.299 0.287 -1.041 0.2980 0.742 0.424 1.309
Smoking -0.038 0.202 -0.190 0.8496 0.962 0.648 1.431
Chronic renal
failure
0.110 0.233 0.475 0.6349 1.117 0.706 1.760
Obesity 0.015 0.194 0.076 0.9396 1.015 0.693 1.485
Conclusions: There is a high prevalence of clopidogrel hyporesponsiveness in patients
presenting with chest pain. Out of multiple potential risk factors, type II diabetes and black
race were the strongest predictors of clopidogrel hyporesponsiveness, followed by gender
and age.
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Platelet Function Testing Predicts Bleeding In Patients Exposed To
Clopidogrel Undergoing Coronary Artery Bypass Grafting
Grant Reed1, Elaine Hoffman1, Amit Kumar2, Andrew Maree3, Dalton McLean4,
Jacki Buros1, Sary Aranki1, Prem Shekar1, Arvind Agnihotri2, Laura Williams1,
Kenneth Rosenfeld2, Christopher Cannon1
1Brigham and Women’s Hospital, Boston, MA, 2Massachusetts General Hospital,
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Background: Clopidogrel use prior to coronary artery bypass grafting (CABG) is
associated with increased bleeding. Whether a bedside platelet function test can predict
bleeding in patients exposed to clopidogrel undergoing CABG is unknown. The aim of
the current study was to determine a level of platelet reactivity as measured by the
VerifyNow™ P2Y12 platelet function assay (Accumetrics, San Diego, CA) above which
CABG can be undertaken in such patients without increased bleeding.
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